PT3712150T - Composto macrocíclico que serve como inibidor wee1 e aplicações do mesmo - Google Patents
Composto macrocíclico que serve como inibidor wee1 e aplicações do mesmoInfo
- Publication number
- PT3712150T PT3712150T PT188744924T PT18874492T PT3712150T PT 3712150 T PT3712150 T PT 3712150T PT 188744924 T PT188744924 T PT 188744924T PT 18874492 T PT18874492 T PT 18874492T PT 3712150 T PT3712150 T PT 3712150T
- Authority
- PT
- Portugal
- Prior art keywords
- applications
- macrocyclic compound
- compound serving
- wee1 inhibitor
- wee1
- Prior art date
Links
- 101100102932 Xenopus laevis wee2-b gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000002678 macrocyclic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711058653 | 2017-11-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3712150T true PT3712150T (pt) | 2024-08-22 |
Family
ID=66332843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT188744924T PT3712150T (pt) | 2017-11-01 | 2018-10-31 | Composto macrocíclico que serve como inibidor wee1 e aplicações do mesmo |
Country Status (21)
Country | Link |
---|---|
US (1) | US11613545B2 (pt) |
EP (1) | EP3712150B1 (pt) |
JP (1) | JP7290638B2 (pt) |
CN (2) | CN111344290B (pt) |
AU (1) | AU2018361010B2 (pt) |
BR (1) | BR112020008664A8 (pt) |
CA (1) | CA3080842A1 (pt) |
DK (1) | DK3712150T3 (pt) |
ES (1) | ES2988855T3 (pt) |
FI (1) | FI3712150T3 (pt) |
HR (1) | HRP20241020T1 (pt) |
HU (1) | HUE067795T2 (pt) |
IL (1) | IL274357B2 (pt) |
LT (1) | LT3712150T (pt) |
PL (1) | PL3712150T3 (pt) |
PT (1) | PT3712150T (pt) |
RS (1) | RS65901B1 (pt) |
SG (1) | SG11202003974XA (pt) |
SI (1) | SI3712150T1 (pt) |
SM (1) | SMT202400319T1 (pt) |
WO (1) | WO2019085933A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3604306B1 (en) * | 2017-03-23 | 2022-10-26 | Shanghai de Novo Pharmatech Co., Ltd. | Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof |
CN112955454A (zh) * | 2018-10-26 | 2021-06-11 | 石家庄智康弘仁新药开发有限公司 | 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用 |
HRP20241008T1 (hr) * | 2019-04-30 | 2024-11-08 | Wuxi Biocity Biopharmaceutics Co., Ltd. | Kristalni oblik spoja inhibitora wee1 i njegova uporaba |
CN112142763B (zh) * | 2019-06-28 | 2024-01-26 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
IL294081A (en) * | 2019-12-20 | 2022-08-01 | Recurium Ip Holdings Llc | Combinations |
CN115103673A (zh) * | 2019-12-20 | 2022-09-23 | 里科瑞尔姆Ip控股有限责任公司 | 组合 |
CN115197221B (zh) * | 2021-04-02 | 2024-05-24 | 轩竹(北京)医药科技有限公司 | 二氢吡唑并嘧啶酮类大环衍生物及其用途 |
TW202328142A (zh) * | 2021-09-18 | 2023-07-16 | 香港商優領醫藥科技(香港)有限公司 | 含嘧啶并二氫吡唑啉酮類衍生物、其藥學上可接受的鹽及其製備方法和應用 |
CN118974048A (zh) * | 2022-02-18 | 2024-11-15 | 英矽智能科技知识产权有限公司 | 膜相关的酪氨酸和苏氨酸特异性cdc2抑制激酶(pkmyt1)抑制剂及其用途 |
WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7163939B2 (en) * | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
AR060635A1 (es) | 2006-04-27 | 2008-07-02 | Banyu Pharma Co Ltd | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer |
WO2008133866A1 (en) | 2007-04-25 | 2008-11-06 | Merck & Co., Inc. | Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor |
AU2008315048A1 (en) | 2007-10-23 | 2009-04-30 | Msd K.K. | Pyridone-substituted-dihydropyrazolopyrimidinone derivative |
AU2009325398A1 (en) | 2008-12-12 | 2010-06-17 | Msd K.K. | Dihydropyrimidopyrimidine derivative |
EP2477628B1 (en) | 2009-09-15 | 2014-08-20 | Merck Sharp & Dohme Corp. | Preparation of crystalline hemihydrate forms of dihydropyrazolopyrimidinone |
US20120232062A1 (en) | 2009-10-20 | 2012-09-13 | Eiger Biopharmaceuticals, Inc. | Azaindazoles to treat flaviviridae virus infection |
TWI532742B (zh) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
EP2731953A1 (en) | 2011-07-15 | 2014-05-21 | Abbvie Inc. | Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases |
WO2013013031A1 (en) | 2011-07-19 | 2013-01-24 | Abbvie Inc. | Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase |
EP2776434A1 (en) | 2011-10-20 | 2014-09-17 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
WO2013126656A1 (en) | 2012-02-23 | 2013-08-29 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
GB201306610D0 (en) | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
JP2016520645A (ja) | 2013-06-06 | 2016-07-14 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッドGlaxosmithkline Intellectual Property No.2 Limited | Zesteホモログ2エンハンサー阻害剤 |
WO2015019037A1 (en) | 2013-08-05 | 2015-02-12 | Almac Discovery Limited | Pharmaceutical compounds |
GB201322602D0 (en) | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
US10947238B2 (en) | 2015-11-01 | 2021-03-16 | The Regents Of The University Of Colorado, A Body Corporate | Wee1 kinase inhibitors and methods of making and using the same |
EP3604306B1 (en) | 2017-03-23 | 2022-10-26 | Shanghai de Novo Pharmatech Co., Ltd. | Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof |
CN112955454A (zh) * | 2018-10-26 | 2021-06-11 | 石家庄智康弘仁新药开发有限公司 | 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用 |
-
2018
- 2018-10-31 PT PT188744924T patent/PT3712150T/pt unknown
- 2018-10-31 SM SM20240319T patent/SMT202400319T1/it unknown
- 2018-10-31 SI SI201831134T patent/SI3712150T1/sl unknown
- 2018-10-31 EP EP18874492.4A patent/EP3712150B1/en active Active
- 2018-10-31 BR BR112020008664A patent/BR112020008664A8/pt unknown
- 2018-10-31 HR HRP20241020TT patent/HRP20241020T1/hr unknown
- 2018-10-31 SG SG11202003974XA patent/SG11202003974XA/en unknown
- 2018-10-31 AU AU2018361010A patent/AU2018361010B2/en active Active
- 2018-10-31 RS RS20240911A patent/RS65901B1/sr unknown
- 2018-10-31 WO PCT/CN2018/112909 patent/WO2019085933A1/zh active Application Filing
- 2018-10-31 US US16/759,769 patent/US11613545B2/en active Active
- 2018-10-31 ES ES18874492T patent/ES2988855T3/es active Active
- 2018-10-31 CN CN201880071103.3A patent/CN111344290B/zh active Active
- 2018-10-31 CN CN202311487748.4A patent/CN117534673A/zh active Pending
- 2018-10-31 CA CA3080842A patent/CA3080842A1/en active Pending
- 2018-10-31 LT LTEPPCT/CN2018/112909T patent/LT3712150T/lt unknown
- 2018-10-31 DK DK18874492.4T patent/DK3712150T3/da active
- 2018-10-31 FI FIEP18874492.4T patent/FI3712150T3/fi active
- 2018-10-31 JP JP2020524447A patent/JP7290638B2/ja active Active
- 2018-10-31 PL PL18874492.4T patent/PL3712150T3/pl unknown
- 2018-10-31 HU HUE18874492A patent/HUE067795T2/hu unknown
-
2020
- 2020-04-30 IL IL274357A patent/IL274357B2/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN111344290A (zh) | 2020-06-26 |
US11613545B2 (en) | 2023-03-28 |
RU2020117443A3 (pt) | 2021-12-01 |
ES2988855T3 (es) | 2024-11-21 |
IL274357A (en) | 2020-06-30 |
LT3712150T (lt) | 2024-08-12 |
EP3712150B1 (en) | 2024-06-12 |
EP3712150A4 (en) | 2021-03-10 |
SG11202003974XA (en) | 2020-05-28 |
CN111344290B (zh) | 2023-12-01 |
DK3712150T3 (da) | 2024-07-29 |
BR112020008664A2 (pt) | 2020-10-27 |
JP2021501191A (ja) | 2021-01-14 |
RS65901B1 (sr) | 2024-09-30 |
SI3712150T1 (sl) | 2024-09-30 |
AU2018361010B2 (en) | 2023-01-12 |
US20200325145A1 (en) | 2020-10-15 |
HRP20241020T1 (hr) | 2024-11-08 |
EP3712150A1 (en) | 2020-09-23 |
HUE067795T2 (hu) | 2024-11-28 |
AU2018361010A1 (en) | 2020-06-11 |
JP7290638B2 (ja) | 2023-06-13 |
CN117534673A (zh) | 2024-02-09 |
IL274357B1 (en) | 2023-01-01 |
FI3712150T3 (fi) | 2024-07-31 |
SMT202400319T1 (it) | 2024-09-16 |
RU2020117443A (ru) | 2021-12-01 |
PL3712150T3 (pl) | 2024-09-02 |
CA3080842A1 (en) | 2019-05-09 |
WO2019085933A1 (zh) | 2019-05-09 |
IL274357B2 (en) | 2023-05-01 |
BR112020008664A8 (pt) | 2023-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL274357A (en) | A macrocyclic compound used as a WEE1 inhibitor and its applications | |
IL273236A (en) | Pyrazolopyrimidine compounds and their uses | |
IL269711B (en) | ask1 inhibitory compounds and uses thereof | |
GB201708652D0 (en) | Novel compounds and uses | |
EP3313449A4 (en) | Ionizable compounds and compositions and uses thereof | |
EP3700934A4 (en) | COMPOUNDS AND USES OF THESE COMPOUNDS | |
EP3529245A4 (en) | COMPOUNDS AND USES OF THE LATEST | |
IL264446A (en) | Compounds and compositions and their use | |
IL288991A (en) | A macrocyclic compound and its uses | |
ZA201906135B (en) | Tri-cycle compound and applications thereof | |
EP3268368A4 (en) | Aza-pyridone compounds and uses thereof | |
EP3368011A4 (en) | NOVEL CONNECTIONS AND USE THEREOF | |
IL264445A (en) | Compounds and compositions and their use | |
EP3247357A4 (en) | Isoergoline compounds and uses thereof | |
EP3558993A4 (en) | AZAINDENOISOQUINOLINE COMPOUNDS AND USES THEREOF |